Gefitinib Plus Chemo for NSCLC With EGFR Mutations Gefitinib Plus Chemo for NSCLC With EGFR Mutations

Dr Mark Kris discusses recent studies that provide evidence for a new standard of care -- gefitinib plus chemotherapy -- in patients with NSCLC and an EGFR-activating mutation.Medscape Oncology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news